Cargando…
High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
Multiple myeloma (MM) growth is supported by an immune-tolerant bone marrow microenvironment. Here, we find that loss of Never in mitosis gene A (NIMA)-related kinase 2 (NEK2) in tumor microenvironmental cells is associated with MM growth suppression. The absence of NEK2 leads to both fewer tumor-as...
Autores principales: | Cheng, Yan, Sun, Fumou, Alapat, Daisy V., Wanchai, Visanu, Mery, David, Guo, Wancheng, Cao, Huojun, Zhu, Yuqi, Ashby, Cody, Bauer, Michael Anton, Nookaew, Intawat, Siegel, Eric R., Ying, Jun, Chen, Jin-Ran, Gai, Dongzheng, Peng, Bailu, Xu, Hongwei, Bailey, Clyde, Al Hadidi, Samer, Schinke, Carolina, Thanendrarajan, Sharmilan, Zangari, Maurizio, Chesi, Marta, Bergsagel, P. Leif, van Rhee, Frits, Janz, Siegfried, Tricot, Guido, Shaughnessy, John D., Zhan, Fenghuang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10591052/ https://www.ncbi.nlm.nih.gov/pubmed/37794587 http://dx.doi.org/10.1016/j.xcrm.2023.101214 |
Ejemplares similares
-
A gene signature can predict risk of MGUS progressing to multiple myeloma
por: Sun, Fumou, et al.
Publicado: (2023) -
CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
por: Gai, Dongzheng, et al.
Publicado: (2022) -
Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
por: Alqazaqi, Raghad, et al.
Publicado: (2022) -
Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
por: Mazahreh, Farah, et al.
Publicado: (2023) -
Variability of definition of high‐risk multiple myeloma across phase III clinical trials
por: Abu Za'nouneh, Faris Jamal, et al.
Publicado: (2023)